KARLSRUHE, Germany, March 4, 2011 /PRNewswire/ — The High Court
of Germany (Bundesgerichtshof) handed down a final ruling in
favor of AmniSure® International, LLC in its dispute with the
Finnish company Medix Biochemica. The court upheld the German
Patent Court’s ruling that the patent associated with Medix’s
ActimPROM test is null and void due to its lack of an inventive
step. Medix is expected to pay AmniSure® an undisclosed amount
to be determined by the courts.
“We are extremely pleased with the decision of the German High
Court,” said Dr. Michael Friedman, President and CEO of
AmniSure® International. “The Court’s decision coincided with
the publication of the new peer-reviewed Guidelines of the European
Association of Perinatal Medicine, which hailed the AmniSure®
test as the ‘most useful tool’ and the ‘most accurate bedside test’
for diagnosing ruptured fetal membranes(1). The Court’s decision
closes a chapter for us by bringing a seven-year-long litigation,
initiated by Medix, to its rightful conclusion. The publication of
the European Guidelines, meanwhile, opens a new chapter for us by
establishing the AmniSure® test as the new benchmark for
diagnosing ruptured fetal membranes.”
(1) The Journal of Maternal-Fetal and Neonatal Medicine, March
2011. ISSN 1476-7058
About AmniSure® International, LLCAmniSure®
International, LLC (http://www.amnisure.com) is a
medical device company that operates internationally with
headquarters in Boston, MA. AmniSure® International pioneered a
rapid diagnostic device, AmniSure® ROM Test, which solves a
long-standing problem in obstetrics and is rapidly becoming a new
global standard in maternal fetal medicine. Contact:
info@amnisure.com 617-234-4441 Tel.This press release was
issued through eReleases(R). For more information, visit
eReleases
